Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Dividend Declaration

4 Oct 2019 16:28

RNS Number : 8846O
CATCo Reinsurance Opps Fund Ltd
04 October 2019
 

 

4 October 2019

 

CATCo Reinsurance Opportunities Fund Ltd. (the "Company")

Interim Dividends

Following the receipt by the Company of additional redemption proceeds from its redemption of the Company's Master Fund Shares, the Company now holds in aggregate $25.154 million of redemption proceeds, and has agreed to return $15.924 million in aggregate by way of interim dividend to Ordinary and C Shareholders.

Consequently, the Board of Directors are declaring interim dividends of $0.0127 in respect of each of the Ordinary Shares and $0.0262 in respect of each of the C Shares for the year to 31 December 2019. The record date for these dividends will be 18 October 2019 and therefore the Ordinary Shares and C Shares will go ex-dividend on 17 October 2019. It is expected that these dividends will be paid to shareholders on 1 November 2019.

The Company intends to use the remaining redemption proceeds (less working capital reserves), being $7.972 million in aggregate, to carry out share buybacks in the market commencing after the ex-dividend date referred to above of 17 October 2019.

The Company anticipates receiving additional redemption proceeds as further side pockets held within the Master Fund are released, and will announce the distribution of these proceeds to Ordinary and C Shareholders as and when these redemption proceeds are received by the Company.

The information in this announcement should be read in conjunction with the full text of the Circular issued by CATCo Reinsurance Opportunities Fund Limited, dated 13 August 2019. Capitalised terms used in this announcement shall, unless the context otherwise requires, bear the meaning given to them in the Circular.

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

For further information:

Markel CATCo Investment Management Ltd.

 

Judith Wynne

General Counsel

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Chief of Investor Marketing

Telephone: +1 441 493 9001

Email: mark.way@markelcatco.com

 

Numis Securities Limited

 

David Benda / Hugh Jonathan

Telephone: +44 (0) 20 7260

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DIVMIBATMBTMBFL
Date   Source Headline
13th Jun 20064:50 pmRNSRule 8.3- Cambridge Antibody
13th Jun 20063:54 pmRNSRule 2.10 Announcement
13th Jun 200612:18 pmRNSEPT Disclosure
13th Jun 200611:42 amRNSEPT Disclosure
13th Jun 200611:35 amRNSEPT Disclosure
13th Jun 200610:20 amRNSEPT Disclosure
12th Jun 20065:35 pmRNSRule 8.3 - Cambridge Antibody
12th Jun 200612:00 pmRNSEPT Disclosure
12th Jun 200611:34 amRNSEPT Disclosure
12th Jun 200611:14 amRNSRule 8.3- (CAT)
12th Jun 200610:08 amRNSEPT Disclosure
12th Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
9th Jun 20061:30 pmRNSRule 8.3- (CAT)
9th Jun 200612:36 pmRNSEPT Disclosure
9th Jun 200611:56 amRNSEPT Disclosure
9th Jun 200611:54 amRNSEPT Disclosure
9th Jun 200611:38 amRNSRule 8.3-Cambridge Antibody
8th Jun 20064:19 pmRNSRule 2.10 Announcement
8th Jun 20062:21 pmRNSEPT Disclosure
8th Jun 20061:14 pmRNSRule 8.3- (CAT)
8th Jun 200610:49 amRNSEPT Disclosure
7th Jun 20065:01 pmRNSHolding(s) in Company
7th Jun 20064:55 pmRNSRule 8.3- Cambridge Anti Tech
7th Jun 200612:38 pmRNSRule 8.3- (CAT)
7th Jun 200612:08 pmRNSEPT Disclosure
7th Jun 200610:00 amRNSOffer for Cambridge Antibody
6th Jun 20064:01 pmRNSRule 8.3- Cambridge Antibody
6th Jun 20063:45 pmRNSRule 8.3- Cambridge Antibody
6th Jun 200612:43 pmRNSEPT Disclosure
5th Jun 20066:00 pmRNSEPT Disclosure
5th Jun 20061:10 pmRNSRule 8.3- (CAT)
5th Jun 200612:55 pmRNSEPT Disclosure
5th Jun 200611:24 amRNSEPT Disclosure
2nd Jun 20062:14 pmRNSEPT Disclosure
2nd Jun 20061:19 pmRNSRule 8.3- (CAT)
2nd Jun 200612:27 pmRNSEPT Disclosure
2nd Jun 200612:22 pmRNSEPT Disclosure
2nd Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
1st Jun 20064:22 pmRNSRule 8.3- Cambridge Antibody
1st Jun 20063:21 pmRNSHolding(s) in Company
1st Jun 200612:25 pmRNSEPT Disclosure
1st Jun 200611:10 amRNSEPT Disclosure
31st May 20063:13 pmRNSRule 8.3- (CAT)
31st May 20063:00 pmRNSMerger Update
31st May 20061:04 pmRNSRule 8.3- Cambridge Antibody
31st May 200611:43 amRNSEPT Disclosure
31st May 200611:27 amRNSEPT Disclosure
31st May 200611:25 amRNSEPT Disclosure
30th May 20063:25 pmRNSRule 8.3- (CAT)
30th May 20063:16 pmRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.